NDATOPICALCREAM
Approved
Mar 2011
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
4/8 — Partial
ZYCLARA (imiquimod) by PharmaIN is interferon inducers [moa]. Approved for actinic keratosis. First approved in 2011.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYCLARA (imiquimod) is a topical cream that works as an interferon inducer to treat actinic keratosis, a precancerous skin condition. Applied directly to affected skin, it activates the immune system to recognize and destroy abnormal cells. The drug represents a non-invasive, office-based alternative to procedural treatments.
LOE Approaching
Product approaching loss of exclusivity with modest market presence ($115K competitor spending noted); expect team restructuring and transition focus toward generic management and indication expansion efforts.
Mechanism of Action
Interferon Inducers
Indications (1)
Clinical Trials (15)
Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma
Started Oct 2025
18 enrolled
Cutaneous Basal Cell Carcinoma
Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma
Started Apr 2020
0Mycosis Fungoides
Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Started Aug 2017
33 enrolled
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)Vulvar DysplasiaVulvar Intraepithelial Neoplasia (VIN)+4 more
Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.
Started May 2017
50 enrolled
Cervical Intraepithelial Neoplasia 3
Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers
Started Feb 2017
16 enrolled
Healthy
Worked on ZYCLARA at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.